286 related articles for article (PubMed ID: 25266026)
1. Therapeutic approaches to gastroesophageal junction adenocarcinomas.
Blom RL; Bogush T; Brücher BL; Chang AC; Davydov M; Dudko E; Leong T; Polotsky B; Swanson PE; van Rossum PS; Ruurda JP; Sagaert X; Tjulandin S; Schraepen MC; Sosef MN; van Hillegersberg R
Ann N Y Acad Sci; 2014 Sep; 1325():197-210. PubMed ID: 25266026
[TBL] [Abstract][Full Text] [Related]
2. Adenocarcinoma at the gastroesophageal junction.
Al-Haddad S; Chang AC; De Hertogh G; Grin A; Langer R; Sagaert X; Salemme M; Streutker CJ; Soucy G; Tripathi M; Upton MP; Vieth M; Villanacci V
Ann N Y Acad Sci; 2014 Sep; 1325():211-25. PubMed ID: 25266027
[TBL] [Abstract][Full Text] [Related]
3. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?
Lin D; Khan U; Goetze TO; Reizine N; Goodman KA; Shah MA; Catenacci DV; Al-Batran SE; Posey JA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e88-e95. PubMed ID: 31099690
[TBL] [Abstract][Full Text] [Related]
4. Cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Surg Oncol; 2000 Jul; 9(1):35-41. PubMed ID: 11525305
[TBL] [Abstract][Full Text] [Related]
5. Cancer of the gastroesophageal junction: combined modality therapy.
Ilson DH
Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
[TBL] [Abstract][Full Text] [Related]
6. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction.
Odenthal M; Hee J; Gockel I; Sisic L; Schmitz J; Stoecklein NH; Driemel C; Möhlendick B; Schmidt T; Knoefel WT; Lang H; Büttner R; Ott K; Vallböhmer D
Int J Cancer; 2015 Jul; 137(1):230-7. PubMed ID: 25429911
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction.
Lagarde SM; ten Kate FJ; Reitsma JB; Busch OR; van Lanschot JJ
J Clin Oncol; 2006 Sep; 24(26):4347-55. PubMed ID: 16963732
[TBL] [Abstract][Full Text] [Related]
8. Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
Leichman L; Pendyala L; Leichman CG
Semin Oncol; 2003 Aug; 30(4 Suppl 11):11-8. PubMed ID: 14506599
[TBL] [Abstract][Full Text] [Related]
9. Esophageal and esophagogastric junction cancers, version 1.2015.
Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
[TBL] [Abstract][Full Text] [Related]
11. Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.
Li Z; Zou X; Xie L; Chen H; Chen Y; Yeung SC; Zhang H
Int J Cancer; 2015 Apr; 136(7):1636-45. PubMed ID: 25159681
[TBL] [Abstract][Full Text] [Related]
12. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
Al-Batran SE; Lorenzen S
Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
[TBL] [Abstract][Full Text] [Related]
13. A Case of Alpha-Fetoprotein-Producing Adenocarcinoma of the Esophagogastric Junction in which Long-Term Survival Was Achieved by Means of Individualized Multidisciplinary Therapy.
Tanaka K; Fujiya M; Ijiri M; Takahashi K; Ando K; Nomura Y; Ueno N; Kashima S; Goto T; Sasajima J; Ito T; Moriichi K; Mizukami Y; Tanabe H; Okumura T
J Gastrointest Cancer; 2019 Sep; 50(3):617-620. PubMed ID: 29457212
[No Abstract] [Full Text] [Related]
14. Management of gastroesophageal junction tumors.
Fox MP; van Berkel V
Surg Clin North Am; 2012 Oct; 92(5):1199-212. PubMed ID: 23026278
[TBL] [Abstract][Full Text] [Related]
15. Early diagnosis and management of esophageal and gastric cancer.
Lang GD; Konda VJ
Minerva Gastroenterol Dietol; 2013 Dec; 59(4):357-76. PubMed ID: 24212354
[TBL] [Abstract][Full Text] [Related]
16. Esophageal and esophagogastric junction cancers.
Ajani JA; Barthel JS; Bentrem DJ; D'Amico TA; Das P; Denlinger CS; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hofstetter WL; Ilson DH; Keswani RN; Kleinberg LR; Korn WM; Lockhart AC; Mulcahy MF; Orringer MB; Osarogiagbon RU; Posey JA; Sasson AR; Scott WJ; Shibata S; Strong VE; Varghese TK; Warren G; Washington MK; Willett C; Wright CD;
J Natl Compr Canc Netw; 2011 Aug; 9(8):830-87. PubMed ID: 21900218
[No Abstract] [Full Text] [Related]
17. Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature.
Bozkurt M; Antonoff M; Jaramillo S; Sagebiel T; Murphy MB
J Gastrointest Cancer; 2019 Sep; 50(3):634-640. PubMed ID: 29577180
[No Abstract] [Full Text] [Related]
18. Concise Commentary: It's All Downhill from Here-How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Gamboa A; Naik R
Dig Dis Sci; 2024 Jan; 69(1):254-255. PubMed ID: 37914891
[No Abstract] [Full Text] [Related]
19. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
[TBL] [Abstract][Full Text] [Related]
20. Carbohydrate antigen 19-9 is a useful prognostic marker in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Uchihara T; Ishimoto T; Nakagawa S; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Oyama S; Shono T; Naoe H; Saeki H; Oki E; Watanabe M; Sasaki Y; Maehara Y; Baba H
Cancer Med; 2015 Nov; 4(11):1659-66. PubMed ID: 26310928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
